FDA OKs Non-Opioid Pain Patch for Post-Herpetic Neuralgia
The FDA approved ZTlido (lidocaine topical system) 1.8% for the treatment of pain associated with post-herpetic neuralgia (PHA), which is caused by shingles.
Officials with the FDA have approved lidocaine topical system (ZTlido, Sorrento Therapeutics) 1.8% for the treatment of pain associated with post-herpetic neuralgia (PHA), according to a press release.
According to Sorrento, the approval of this product marks significant progress for analgesics because it can deliver pain relief for up to 12 hours, including during exercise.
“ZTlido was designed to solve a problem that is commonly reported with transdermal/topical patches: they don’t stay on. Based on the adhesion study results with ZTlido, we believe that ZTlido product will be welcomed by health care providers, patients, and payers who are looking for an effective and efficient, local pain treatment,” Henry Ji, PhD, chairman and CEO of Sorrento and Scilex, said in a press release. “We also intend to explore the expansion of ZTlido into additional indications and the underlining platform technology of ZTlido for other active pharmaceutical ingredients (APIs) and combinations of APIs.”
ZTildo is based on new technology that allows for superior adhesion and drug delivery, according to the release.
Notably, ZTlido requires a 36-mg/topical system compared with a 700-mg/patch of Lidoderm (lidocaine patch 5%) to achieve the same dose, Sorrento reported.
For more information on this approval, go to SpecialtyPharmacyTimes.com
